| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Reports record revenue of $1,023.6 million, up 7% year-over-year, net income of $20.3 million, up 1,782% year-over-year, and record adjusted EBITDA(1) of $77.2 million, up 13% year-over-year for the three months ended September 30, 2026 |
| 23 Sep 2026 |
8-K: Regulation FD Disclosure
2 Forward Looking Statements This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , Section 27A of the Securities Act and Section 21E of the Exchange Act. Forw... |
| 23 Sep 2026 |
8-K: Material Cybersecurity Incidents
Astrana Health, Inc. (the “Company”) recently became aware that its subsidiary Astrana Health Management, Inc. detected unusual activity within its environment. |
| 15 Sep 2026 |
8-K: Regulation FD Disclosure
2 Forward Looking Statements This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , Section 27A of the Securities Act and Section 21E of the Exchange Act. Forw... |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Reports revenue of $972.5 million, up 49% year-over-year, net income of $18.5 million, up 81% year-over-year, and adjusted EBITDA(1) of $68.9 million, up 43% year-over-year for the three months ended June 30, 2026 |
| 13 Jul 2026 |
8-K: Regulation FD Disclosure
ALHAMBRA, Calif., July 13, 2026/PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a physician-centric, technology-enabled healthcare company empower... |
| 01 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 10 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
(a) Establishment; Amendment and Restatement. Astrana Health, Inc. (the “Company”) originally established the Astrana Health, Inc. 2024 Equity Incentive Plan, effective as of February 28, 2024 (the “Effective Date”), and the Plan was ori... |
| 12 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 12 May 2026 |
8-K: Regulation FD Disclosure
M e d i c a r e M e d i c a i d C o m m e r c i al O th e r T h i r d P a r t i es F u l l - r i s k P art i a l - r i sk F u l l - r i s k P art i a l - r i sk C a p i t at i o n , n e t R i s k P o o l S et t l e m e n t s & I n c e nt... |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Reports total revenue of $965.1 million, up 56% year over year |
| 30 Mar 2026 |
8-K: Other Events
As of June 30, 2025 and September 30, 2024 and for the Nine Months Ended June 30, 2025 and 2024 |
| 04 Mar 2026 |
8-K: Regulation FD Disclosure
2 Forward Looking Statements This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , Section 27A of the Securities Act and Section 21E of the Exchange Act. Forw... |
| 02 Mar 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
Reports total revenue for the year ended of $3,181.8 million, up 56% year-over-year, and at the higher end of guidance |
| 12 Jan 2026 |
8-K: Regulation FD Disclosure
2 Forward Looking Statements This presentation contains forward -looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , Section 27A of the Securities Act and Section 21E of the Exchange Act. Forwa... |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Reports total revenue of $956.0 million, up 100% year-over-year, and at the higher end of guidance |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition
Reports total revenue of $654.8 million and adjusted EBITDA of $48.1 million, both at the higher end of guidance |
| 02 Jul 2025 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +2 more
ALHAMBRA, Calif., July 2, 2025 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a physician-centric, technology-enabled healthcare company empower... |
| 11 Jun 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
(a) Establishment. Astrana Health, Inc. (the “Company”) originally established the Astrana Health, Inc. 2024 Equity Incentive Plan, effective as of February 28, 2024 (the “Effective Date”), subject to the approval of the Plan by the stoc... |
| 04 Jun 2025 |
8-K: Regulation FD Disclosure
On June 4, 2025, Astrana Health, Inc. (the “Company”) updated its corporate presentation that it intends to use in connection with presentations at conferences and meetings. The slides from the Company’s corporate presentation are attach... |
Loading...